Annovis Bio Inc
ANVS2.643USD
+0.133+5.31%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
51.51MCap. mercado
PérdidaP/E TTM
Más Datos de Annovis Bio Inc Compañía
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Información de la empresa
Símbolo de cotizaciónANVS
Nombre de la empresaAnnovis Bio Inc
Fecha de salida a bolsaJan 29, 2020
Director ejecutivoDr. Maria L. Maccecchini, Ph.D.
Número de empleados8
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 29
Dirección101 Lindenwood Drive, Suite 225
CiudadMALVERN
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal19355
Teléfono14848753192
Sitio Webhttps://www.annovisbio.com/
Símbolo de cotizaciónANVS
Fecha de salida a bolsaJan 29, 2020
Director ejecutivoDr. Maria L. Maccecchini, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.67M
+1.52%
Mr. Andrew Walsh
Mr. Andrew Walsh
Vice President - Finance, Principal Financial Officer
Vice President - Finance, Principal Financial Officer
500.00
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Eve Damiano
Eve Damiano
Senior Vice President - Regulatory
Senior Vice President - Regulatory
--
--
,
,
Vice President - Process Chemistry
Vice President - Process Chemistry
--
--
Cheng Fang
Cheng Fang
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.67M
+1.52%
Mr. Andrew Walsh
Mr. Andrew Walsh
Vice President - Finance, Principal Financial Officer
Vice President - Finance, Principal Financial Officer
500.00
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 19 de jul
Actualizado: sáb., 19 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Hoffman (Michael B)
8.57%
Maccecchini (Maria-Luisa)
5.72%
Heights Capital Management, Inc.
5.13%
The Vanguard Group, Inc.
3.33%
Two Sigma Investments, LP
1.33%
Other
75.93%
Accionistas
Accionistas
Proporción
Hoffman (Michael B)
8.57%
Maccecchini (Maria-Luisa)
5.72%
Heights Capital Management, Inc.
5.13%
The Vanguard Group, Inc.
3.33%
Two Sigma Investments, LP
1.33%
Other
75.93%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
14.69%
Investment Advisor
11.83%
Investment Advisor/Hedge Fund
1.76%
Hedge Fund
1.75%
Research Firm
0.51%
Family Office
0.10%
Bank and Trust
0.05%
Pension Fund
0.03%
Other
69.28%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
103
5.97M
30.62%
-274.28K
2025Q1
104
5.95M
41.64%
-106.94K
2024Q4
93
4.41M
22.61%
-199.92K
2024Q3
85
4.03M
23.62%
-296.86K
2024Q2
80
3.84M
23.67%
-697.75K
2024Q1
77
3.92M
38.68%
-550.67K
2023Q4
77
3.92M
40.01%
-464.08K
2023Q3
81
3.83M
42.48%
-299.71K
2023Q2
104
3.90M
43.31%
-104.02K
2023Q1
106
3.34M
40.86%
-680.15K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Hoffman (Michael B)
1.67M
8.57%
+25.00K
+1.52%
Jun 13, 2025
Maccecchini (Maria-Luisa)
1.11M
5.72%
+46.00K
+4.31%
Jun 04, 2025
Heights Capital Management, Inc.
1.00M
5.13%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
647.92K
3.33%
+181.64K
+38.96%
Mar 31, 2025
Two Sigma Investments, LP
259.14K
1.33%
+248.22K
+2272.43%
Mar 31, 2025
UBS Financial Services, Inc.
160.88K
0.83%
+112.14K
+230.10%
Mar 31, 2025
Geode Capital Management, L.L.C.
152.61K
0.78%
+53.05K
+53.28%
Mar 31, 2025
Susquehanna International Group, LLP
127.70K
0.66%
+72.39K
+130.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
99.49K
0.51%
-1.29K
-1.28%
Mar 31, 2025
Consilium Associates
97.82K
0.5%
-700.00
-0.71%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
